Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | TERT | O14746 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 3/20 | 0.55 |
| ▸ | PPARD | Q03181 | 3/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | TOP1 | P11387 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | FABP4 | P15090 | 2/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358160 | 1.00 | CA2 (0.66) | CA2MAPK1TERTPTPN1PPARG | |
| SCHEMBL1015155 | 1.00 | CA2 (0.66) | CA2MAPK1TERTPTPN1PPARG | |
| SCHEMBL1116087 | 1.00 | CA2 (0.66) | CA2MAPK1TERTPTPN1PPARG | |
| SCHEMBL358162 | 1.00 | CA2 (0.66) | CA2MAPK1TERTPTPN1PPARG | |
| SCHEMBL11301832 | 1.00 | CA2 (0.66) | CA2MAPK1TERTPTPN1PPARG | |
| SCHEMBL11301839 | 1.00 | CA2 (0.66) | CA2MAPK1TERTPTPN1PPARG | |
| SCHEMBL3022238 | 1.00 | CA2 (0.66) | CA2MAPK1TERTPTPN1PPARG | |
| SCHEMBL28430518 | 0.96 | CA2 (0.66) | CA2MAPK1TERTPTPN1PPARG | |
| SCHEMBL10906977 | 0.95 | CA2 (0.59) | CA2MAPK1PPARGPPARDPPARA | |
| SCHEMBL10906974 | 0.95 | CA2 (0.59) | CA2MAPK1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200323975-A1 | VACCINATION WITH REPLICON PARTICLES AND OIL ADJUVANT | INTERVET INC. (US) | 2020-10-15 | — | — | US | claimed |
| US-20200237920-A1 | STABLE INJECTABLE PHARMACEUTICAL COMPOSITION OF NEUROKININ 1 RECEPTOR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF | PHARMATHEN S.A. (GR) | 2020-07-30 | — | — | US | claimed |
| EP-2866797-B1 | STABLE INJECTABLE PHARMACEUTICAL COMPOSITION OF NEUROKININ 1 RECEPTOR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF | PHARMATHEN SA (GR) | 2020-04-29 | — | — | EP | claimed |
| US-20190328828-A1 | PHARMACEUTICAL COMPOSITION, PROCESS FOR PRODUCING THE SAME, USE OF A PEPTIDE, USE OF A PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DISEASES ASSOCIATED WITH INTRAOCULAR HYPERTENSION OR GLAUCOMA | UNIÃO QUIMICA FARMACEUTICA NACIONAL S/A (BR) | 2019-10-31 | — | — | US | claimed |
| CN-103910738-B | A kind of Bisbenzylisoquinolincompounds quaternary ammonium salt and preparation method thereof and the application in preparing antitumor drug | 山东师范大学 | 2016-07-06 | — | — | CN | claimed |
| CN-103910741-B | Bisbenzylisoquinolincompounds trimethyl-glycine and preparation method thereof and the application in antitumor drug preparation | Shangdong Normal University (CN) | 2016-04-13 | — | — | CN | claimed |
| US-20150165045-A1 | STABLE INJECTABLE PHARMACEUTICAL COMPOSITION OF NEUROKININ 1 RECEPTOR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF | PHARMATHEN S.A. (GR) | 2015-06-18 | — | — | US | claimed |
| EP-2866797-A1 | STABLE INJECTABLE PHARMACEUTICAL COMPOSITION OF NEUROKININ 1 RECEPTOR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF | Pharmathen S.A. (GR) | 2015-05-06 | — | — | EP | claimed |
| WO-2014005606-A1 | STABLE INJECTABLE PHARMACEUTICAL COMPOSITION OF NEUROKININ 1 RECEPTOR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF | PHARMATHEN S.A. (GR) | 2014-01-09 | — | — | WO | claimed |
| WO-2006128266-A2 | PHARMACEUTICAL COMPOSITIONS OF THE PEPTIDE ANGIOTENSIN-(1 -7) [ANG-(I -7)] AND ITS ANALOGUES, AGONISTS AND ANTAGONISTS, FOR USE IN CONTROLLING THE FUNCTIONS OF THE REPRODUCTIVE SYSTEM | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2006-12-07 | — | — | WO | claimed |
| EP-3828163-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | AUTOTAC INC (KR) | 2026-05-20 | — | — | EP | disclosed |
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | MEDIHELPLINE CO., LTD (KR) | 2026-05-05 | — | — | US | disclosed |
| WO-2025262124-A1 | ADJUVANTED VETERINARY VACCINES AGAINST ENTERIC DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025262123-A1 | VETERINARY VACCINES AGAINST ENTERIC DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2025-12-26 | — | — | WO | disclosed |
| US-12502426-B2 | Inactivated piscine orthoreovirus vaccine | INTERVET INC. (US) | 2025-12-23 | — | — | US | disclosed |
| EP-0537318-B1 | NEW NON-HYGROSCOPIC MONO-AMMONIUM SALTS | MONSANTO EUROPE SA (BE) | 1996-06-12 | — | — | EP | disclosed |
| US-5410075-A | Salt formation; used as pesticides, herbicides and plant growth regulators | ALKALOIDA VEGYESZETI GYAR RT. (HU) | 1995-04-25 | — | — | US | disclosed |
| EP-0424865-B1 | Removal of dioxins and furans | SPRINTSYSTEM GMBH (DE) | 1994-12-28 | — | — | EP | disclosed |
| US-5324708-A | Mixed with herbicide, plant growth regulator in bag | AKLALOIDA VEGYESZETI GYAR RT. (HU) | 1994-06-28 | — | — | US | disclosed |
| US-4151188-A | COMBATTING FILARIASIS IN DOGS | FRIEDHEIM ERNST A H (CH) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | CUTA, VEGFA, MMP8 | CA2 2680/4885MAPK1 2395/4885TERT 4094/4885 |
| US-12502426-B2 | Inactivated piscine orthoreovirus vaccine | AZI2, UNC119, ICOS | CA2 3854/4885MAPK1 2794/4885TERT 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.